Artesunate is under clinical development by Frantz Viral Therapeutics and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According to GlobalData, Phase II drugs for Human Papillomavirus (HPV) Associated Cancer have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Artesunate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Artesunate is under development for the treatment of human papillomavirus (HPV) associated cervical intraepithelial neoplasia (CIN) and anal intraepithelial neoplasia (AIN). It is administered as a suppository.
For a complete picture of Artesunate’s drug-specific PTSR and LoA scores, buy the report here.